Posters

Psych Congress Criminal Justice
Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study
Psych Congress Criminal Justice
Partners in Mental Health: Certified PAs as an Innovative Strategy to Expand Access
Psych Congress Criminal Justice
Descriptive Patterns Emerging From Initial Antidepressant Treatment Episodes in Patients with Treatment-Resistant Depression
Psych Congress Criminal Justice
A Novel, Modified Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes
Psych Congress Criminal Justice
The Efficacy and Safety of Aripiprazole Once-Monthly 400mg (AOM 400) in African American/Black Patients Compared to Non-African American/Black Patients
Psych Congress Criminal Justice
A Qualitative Assessment of Reasons for Frequent Emergency Department Utilization Among Patients With Serious Mental Illness
Psych Congress Criminal Justice
Validity of the Spanish Language Version of the HERO Wellness Scale: Report From Mental Health Professionals and General Community
Psych Congress Criminal Justice
Medication Madness: Aripiprazole-Induced Psychosis
Psych Congress Criminal Justice
Dasotraline for Treatment of Adults With Binge-Eating Disorder: Effect on Binge-related Obsessions and Compulsions
Psych Congress Criminal Justice
Determining Meaningful Change in Depression Symptoms Assessed With the Patient Health Questionnaire (PHQ-9) and Sheehan Disability Scale (SDS) Among Patients With Treatment Resistant Depression in Trials of Esketamine Nasal Spray
Psych Congress Criminal Justice
Efficacy and Cost Analysis of Assisted Outpatient Treatment Program for Severely Mentally Ill Patients in a Small Alabama Community
Psych Congress Criminal Justice
Consistent Efficacy of Lofexidine Across Primary and Secondary Efficacy Outcomes in a Large, Placebo-Controlled Trial
Psych Congress Criminal Justice
Evaluation of Depression Severity Items on the Patient Health Questionnaire (PHQ-9) and Sheehan Disability Scale (SDS) in Patients With Treatment-Resistant Depression Treated With Esketamine Nasal Spray
Psych Congress Criminal Justice
Extended-Release Viloxazine (SPN-812) 100 mg or 200 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301)
Psych Congress Criminal Justice
Use of Supportive Medication for Opioid Withdrawal Syndrome in a Randomized, Placebo-Controlled Trial of Lofexidine
Psych Congress Criminal Justice
Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia
Psych Congress Criminal Justice
Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Adolescents: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302)
Psych Congress Criminal Justice
Pooled Analysis From 12-Week Randomized, Controlled Studies of Solriamfetol in the Treatment of Excessive Daytime Sleepiness in Participants With Obstructive Sleep Apnea or Narcolepsy
Psych Congress Criminal Justice
Single-Dose Pharmacokinetics of Amphetamine Extended-Release Tablet (AMPH ER TAB) Compared With Amphetamine Extended-Release Oral Suspension (AMPH EROS)
Psych Congress Criminal Justice
Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303)
Psych Congress Criminal Justice
Barriers and Drivers of Adopting a Digital Medication Adherence Technology: Understanding the Factor Analysis Results
Psych Congress Criminal Justice
Response Patterns for Digital Medicine Missed Dose Surveys in Patient with Serious Mental Illness
Psych Congress Criminal Justice
Hospitalization Risk in Pediatric Bipolar Patients Treated with Lurasidone vs. Other Oral Atypical Antipsychotics: A Real-World Retrospective Claims Database Study
Psych Congress Criminal Justice
A Comparison of Barriers and Drivers Between Prescribing and Non-Prescribing Psychiatric Care Providers Regarding Use of Digital Medication Adherence Platforms
Psych Congress Criminal Justice
Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial
Back to Top